Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-28T09:08:47.623Z Has data issue: false hasContentIssue false

Molecular and therapeutic aspects of varicella–zoster virus infection

Published online by Cambridge University Press:  10 August 2005

Mark Quinlivan
Affiliation:
Skin Virus Laboratory, Institute of Cell and Molecular Science, 4 Newark Street, Whitechapel, London, E1 28E, UK.
Judith Breuer
Affiliation:
Skin Virus Laboratory, Institute of Cell and Molecular Science, 4 Newark Street, Whitechapel, London, E1 28E, UK.

Abstract

Varicella–zoster virus (VZV) is a highly species-specific member of the Herpesviridae family. The virus exhibits multiple cell tropisms, infecting peripheral blood mononuclear cells and skin cells before establishing latency in sensory neurons. Such tropisms are essential both for primary infection, which manifests itself as chickenpox (varicella), and subsequent reactivation to cause herpes zoster (shingles). The highly cell-associated nature of the virus, coupled with its narrow host range, has resulted in the lack of an animal model that mimics its diseases in humans, thereby greatly hindering the study of events in VZV pathogenesis. Despite this, extensive studies both in vitro and in vivo in small-animal models have provided a fascinating insight into molecular events that govern VZV diseases. In addition, VZV has become the first human herpes virus for which a live attenuated vaccine has been developed.

Type
Review Article
Copyright
© Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)